SCYX News and Press, SCYNEXIS Inc. From 12/29/23

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and ...

NEW YORK, NY / ACCESSWIRE / December 20, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SCYNEXIS, Inc. ("Scynexis" or "the Company") (NASDAQ:SCYX). Investors who purchased Scynexis securities prior to March 31, 2023, and continue to hol...

2023-12-18 18:46:23 ET Summary Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance. The company's approved product, ibrexafungerp, has been licensed to GSK with anticipated peak sales of over $500M. Ibrexafungerp commercialization ...

Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and Sept...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Scynexis between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights,...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Scynexis between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights,...

2023-11-20 07:00:00 ET Summary We maintain our sell rating due to the company's voluntary recall of its flagship product, Brexafemme, and concerns over manufacturing challenges. The recall has had a significant impact on SCYX stock price and raises doubts about its growth trajecto...

2023-11-14 10:18:51 ET More on SCYNEXIS Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade) Seeking Alpha’s Quant Rating on SCYNEXIS Historical earnings data for SCYNEXIS For further details see: SCYNEXIS ...

IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advance Remediation strategies following the voluntary recall of BREXAFEMME ® and the MARIO study clinical hold are being evaluated ...